Leap Therapeutics Secures $58.88 Million for Digital Asset Strategy

According to Foresight News, biotechnology company Leap Therapeutics, listed on NASDAQ under the ticker LPTX, has announced a $58.88 million private placement led by Winklevoss Capital. This funding aims to initiate a digital asset financial strategy. Winklevoss Capital will provide both financial and strategic support to assist Leap in developing and implementing its digital asset strategy. Leap Therapeutics plans to leverage Winklevoss Capital's expertise to engage actively in digital asset investments, with the goal of creating long-term value for its shareholders. A portion of the funds will be allocated to the continued development of Leap's therapeutic programs, including FL-501 and sirexatamab.